FluoGuide is a clinical stage biotechnology company dedicated to developing drugs that enhance surgical outcomes by making cancer cells fluorescent. Their primary product, FG001, utilizes their proprietary uPAR technology platform, which creates fluorescence in cancer cells during surgery. Injected intravenously prior to surgery, FG001 has been proven to be safe and well-tolerated in an ongoing phase IIa clinical trial.

By leveraging their uPAR-targeted luminescent technology, FluoGuide's platform enables surgeons to differentiate cancerous tissue from normal tissue, reducing the risk of leaving malignant cells behind and preserving healthy tissue. Additionally, their platform can potentially be used for photothermal treatments to induce cancer cell death. With a focus on solid cancers such as brain, lung, breast, colorectal, head & neck, and pancreatic cancers, FluoGuide's products have the potential to benefit at least three million patients annually.

They are listed on Nasdaq First North- Growth Market under the ticker FLUO